Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Solid Biosciences Inc (SLDB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 326,246
  • Shares Outstanding, K 35,423
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,800 K
  • 60-Month Beta 1.83
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.49

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/19
See More
  • Average Estimate -0.61
  • Number of Estimates 2
  • High Estimate -0.57
  • Low Estimate -0.64
  • Prior Year -0.54
  • Growth Rate Est. (year over year) -12.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.45 +8.99%
on 04/16/19
10.88 -15.35%
on 03/21/19
-1.22 (-11.70%)
since 03/18/19
3-Month
5.97 +54.27%
on 02/07/19
26.70 -65.51%
on 01/22/19
-16.50 (-64.18%)
since 01/18/19
52-Week
5.97 +54.27%
on 02/07/19
54.84 -83.21%
on 06/19/18
-1.53 (-14.25%)
since 04/18/18

Most Recent Stories

More News
Research Report Identifies Solid Biosciences, Zion Oil & Gas, Banner, Senestech, Kingsway Financial Services, and Marathon Patent Group with Renewed Outlook -- Fundamental Analysis, Calculating Forward Movement

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Solid Biosciences Inc. (NASDAQ:SLDB),...

MARA : 3.30 (+10.74%)
SLDB : 9.21 (+4.66%)
ZN : 0.70 (-8.44%)
KFS : 2.41 (-1.23%)
BANR : 54.64 (-1.64%)
SNES : 1.45 (+2.84%)
Wave Life Sciences Plunges After DMD Study Data Readout

Wave Life Sciences (WVE) announces final safety data from a phase I DMD study evaluating suvodirsen and provides design update for phase II/III stage development of the candidate.

SLDB : 9.21 (+4.66%)
SRPT : 116.64 (-1.76%)
WVE : 25.58 (-1.65%)
PFE : 39.38 (-1.25%)
4 Gene Therapy Players Likely to Become Buyout Targets in 2019

Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
SRPT : 116.64 (-1.76%)
OPHT : 1.39 (-0.71%)
NITE : 25.51 (+0.04%)
RGNX : 54.65 (-0.13%)
BOLD : 38.90 (+0.96%)
Solid Biosciences Reports Fourth Quarter and Fiscal Year 2018 Financial Results and Provides Business Update

Solid Biosciences Inc. (NASDAQ: SLDB) today reported financial results for the fourth quarter and fiscal year ended December 31, 2018 and provided a business update.

SLDB : 9.21 (+4.66%)
The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

The Zacks Analyst Blog Highlights: Spark Therapeutics, Solid Biosciences, REGENXBIO, Editas Medicine and uniQure

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
RGNX : 54.65 (-0.13%)
EDIT : 25.80 (+0.31%)
Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
PBE : 51.76 (-0.46%)
SBIO : 33.66 (+0.18%)
CRSP : 36.26 (-0.47%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
BLUE : 137.06 (-1.67%)
NVS : 76.41 (-1.15%)
BOLD : 38.90 (+0.96%)
RHHBY : 32.6900 (-0.09%)
XBI : 84.63 (-0.24%)
5 Gene Therapy Stocks to Enrich Your Portfolio

Gene therapy stocks have not only soared on Roche-Spark deal news but are also poised to make the most of the next gene revolution.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
ONCE : 110.62 (-0.08%)
RGNX : 54.65 (-0.13%)
EDIT : 25.80 (+0.31%)
RHHBY : 32.6900 (-0.09%)
Biotech ETFs Jump on Roche-Spark Deal

The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.

QURE : 53.70 (-1.68%)
SLDB : 9.21 (+4.66%)
PBE : 51.76 (-0.46%)
SBIO : 33.66 (+0.18%)
CRSP : 36.26 (-0.47%)
ARKG : 32.12 (+0.44%)
ONCE : 110.62 (-0.08%)
BLUE : 137.06 (-1.67%)
NVS : 76.41 (-1.15%)
BOLD : 38.90 (+0.96%)
RHHBY : 32.6900 (-0.09%)
XBI : 84.63 (-0.24%)
Sarepta's NDA for DMD Drug Golodirsen Gets Priority Review

FDA accepts Sarepta's (SRPT) regulatory application seeking approval for DMD therapy, golodirsen, and grants priority review. A decision is expected in August 2019.

SLDB : 9.21 (+4.66%)
SRPT : 116.64 (-1.76%)
PFE : 39.38 (-1.25%)
SRRK : 17.43 (+4.06%)
SHAREHOLDER ALERT: Investigation of Solid Biosciences Inc. Announced by Holzer & Holzer, LLC

Holzer & Holzer, LLC is investigating whether certain statements made by Solid Biosciences, Inc. ("Solid Biosciences" or the "Company") (NASDAQ: SLDB) complied with federal securities laws....

SLDB : 9.21 (+4.66%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade SLDB with:

Business Summary

Solid Biosciences LLC is a life science company. It focuses on developing therapies for Duchenne muscular dystrophy. The company is engaged in developing gene therapies, disease modifying therapies and assistive devices, all targeting the various facets of the DMD. Its product candidate includes SGT-001,...

See More

Key Turning Points

2nd Resistance Point 9.63
1st Resistance Point 9.42
Last Price 9.21
1st Support Level 8.90
2nd Support Level 8.59

See More

52-Week High 54.84
Fibonacci 61.8% 36.17
Fibonacci 50% 30.41
Fibonacci 38.2% 24.64
Last Price 9.21
52-Week Low 5.97

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar